Tags

Type your tag names separated by a space and hit enter

Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
Lancet 2003; 362(9395):1513Lct

Authors+Show Affiliations

Department of Clinical Neurosciences, Foothills Medical Center, Alberta, T2N 2T9, Calgary, Canada. lmetz@ucalgary.caNo affiliation info available

Pub Type(s)

Comment
Comparative Study
Journal Article

Language

eng

PubMed ID

14615102

Citation

Metz, Luanne, and Stacey Page. "Oral Cannabinoids for Spasticity in Multiple Sclerosis: Will Attitude Continue to Limit Use?" Lancet (London, England), vol. 362, no. 9395, 2003, p. 1513.
Metz L, Page S. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet. 2003;362(9395):1513.
Metz, L., & Page, S. (2003). Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet (London, England), 362(9395), p. 1513.
Metz L, Page S. Oral Cannabinoids for Spasticity in Multiple Sclerosis: Will Attitude Continue to Limit Use. Lancet. 2003 Nov 8;362(9395):1513. PubMed PMID: 14615102.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? AU - Metz,Luanne, AU - Page,Stacey, PY - 2003/11/15/pubmed PY - 2004/2/5/medline PY - 2003/11/15/entrez SP - 1513 EP - 1513 JF - Lancet (London, England) JO - Lancet VL - 362 IS - 9395 SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/14615102/Oral_cannabinoids_for_spasticity_in_multiple_sclerosis:_will_attitude_continue_to_limit_use L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(03)14776-9 DB - PRIME DP - Unbound Medicine ER -